Posts filtered by tags: Biotech[x]


 

Xconomy’s Seattle Event to Explore Tech Convergence in Life Sciences

The lines between biotech and high tech are blurring, and Seattle is one of the country’s hotspots for this convergence. IT innovations for analyzing big data are finding applications in drug discovery research. Smartphones can now be used to collect clinical data and also deliver a new wave of “digital treatments.”On June 25, Xconomy will hold its annual Seattle Life Science Xchange event at Cambia Grove. The program will bring together founders and innovators from the Puget Sound region who w...
Tags: National blog main, Seattle, Seattle blog main, Seattle top stories, Biotech, Cambia Grove, Digital Therapeutics, Digital Therapy, Drug Discovery, HealthIT, Infectious Disease Research Institute, Life Sciences, Litesprite, Startups, Steve Reed, Swatee Surve


Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More

Persistence and perseverance were the themes of two of our top stories this week.First there’s the story of Nationwide Children’s Hospital. The Columbus, Ohio, hospital chose to invest in gene therapy when the field was in its darkest days. After some ups and downs, the team it put in place helped advance some of the most promising gene therapies currently in human testing—and put Nationwide in the national spotlight as one of those treatments nears FDA approval.Then there’s Suzanne Ildstad. A ...
Tags: Deals, Startups, Usa, Trends, Vc, Fda, National, University of Pennsylvania, Novartis, Allergan, Biotech, Crispr, Life Sciences, Clinical Trials, Amgen, Gilead Sciences


Hookipa’s IPO Raises $84M for Drugs to Reprogram the Immune System

Hookipa Pharma has raised $84 million in an initial public offering that will fund development of experimental treatments developed to reprogram the immune system to treat infectious diseases and cancer.But Hookipa (NASDAQ: HOOK) had to downsize its IPO, offering only 6 million shares at $14 apiece. That was the low end of its targeted $14 to $16 range. Hookipa had initially planned to sell 6.7 million shares. In the first day of trading Thursday, Hookipa shares hovered around the IPO price.Hoo...
Tags: Deals, New York, Ipo, Hiv, Trends, Investing, Prostate Cancer, Immunotherapy, Biotech, Life Sciences, Clinical Trials, Gilead Sciences, National blog main, San Francisco blog main, Hookipa, Cancer Immunotherapy


Bardy Diagnostics to Ramp Up Cardiac Monitor Sales With $35M Raise

Bardy Diagnostics, a Seattle-based business developing a cardiac monitor and arrhythmia detection device, announced this week it has raised $35.5 million from investors to hire additional salespeople and fund continued product development.Bardy’s flagship device is an hourglass-shaped patch that Bardy says is designed to be placed on the center of the patient’s chest, over the heart, to diagnose arrhythmia, an irregular heartbeat condition. Patients can wear the patch, which Bardy calls the Car...
Tags: Deals, Startups, Trends, Vc, Healthcare, Heart Health, Heart, Biotech, Seattle, Life Sciences, Medical Devices, Cam, Boston Scientific, Ascension Ventures, Welch Allyn, Bardy


It’s Tough to Find Drugs to Bind to RNA: Arrakis Nabs $75M to Help

Arrakis Therapeutics has been scouting elusive pharmaceutical quarry: small molecules able to “drug” RNA, the molecular messengers that carry the genetic instructions for proteins. Most drugs in use today act on proteins. But CEO Michael Gilman says targeting the genetic blueprints could prevent RNA from translating those instructions into disease-causing proteins in the first place.Waltham, MA-based Arrakis is now ramping up to turn its discoveries into potential drugs and it has $75 million t...
Tags: Deals, Boston, Cancer, Trends, Investing, Vc, Venture Capital, Novartis, Biotech, Life Sciences, Celgene, Roche, Gilman, Alexandria Venture Investments, Osage University Partners, University of North Carolina at Chapel Hill


MedHealth Summit Brings Together Cross-Border Innovators and Experts

As the healthcare industry continues to undergo technology-driven changes, innovators in digital health and medical devices will gather in Detroit Thursday for a daylong conference.The MedHealth Summit, held at Ford Field’s Hall of Legends, will bring together experts and entrepreneurs from across Southeast Michigan and Southwest Ontario for a day of panel discussions, “investor speed dating,” and business matchmaking between various industry stakeholders. Online registration for the event is c...
Tags: Startups, Entrepreneurship, Trends, Tech, Software, Innovation, Healthcare Industry, Biotech, Detroit, Digital Health, Life Sciences, Healthtech, Southeast Michigan, National blog main, Detroit blog main, Detroit top stories


Flagship Pioneering Unveils Kintai’s Gut Approach to Treating Disease

The gastrointestinal system is often viewed as a barrier to drugs. Conditions ideal for breaking down food also break down drugs in ways that can limit how well they work. Interaction with the gut microbiome can also diminish a drug’s efficacy or boost its toxicity.Paul-Peter Tak, a former GlaxoSmithKline (NYSE: GSK) executive who is now the CEO of Cambridge, MA-based Kintai Therapeutics, contends that the gut and its microflora can also open up new ways to treat an array of diseases throughout...
Tags: Startups, Drugs, Boston, Cancer, Trends, Ulcerative Colitis, Venture Capital, GlaxoSmithKline, Parkinson's Disease, Biotech, Microbiome, Metabolism, Life Sciences, Clinical Trials, GSK, Cambridge MA


Hatteras Launches New Fund With $94M for Life Science Investments

Hatteras Venture Partners is kicking off its latest fund with $94 million it plans to deploy to life sciences startups.The cash committed so far is the first closing of a fund that Hatteras says could reach up to $200 million. It’s the sixth fund for Durham, NC-based Hatteras. The venture capital firm invests throughout the US but focuses on the Southeast, which has fewer venture capital firms compared to regions such as Silicon Valley, Boston, and New York.Hatteras says it plans to use the dry...
Tags: Drugs, US, Trends, Investing, Vc, Venture Capital, Biotech, Life Sciences, Southeast, Medical Devices, Durham NC, Diagnostics, National blog main, Raleigh-Durham blog main, HealthIT, Raleigh-Durham


AskBio Reels In $235M to Advance Gene Therapy Clinical Trials

Asklepios BioPharmaceutical (AskBio) has raised $235 million in financing to support its research and development of gene therapies for rare, genetic disorders.The funding came from TPG Capital and Vida Ventures, which together invested $225 million and gained a minority stake in the Research Triangle Park, NC, company. Concurrent with that investment, AskBio’s founders and board members invested $10 million. The AskBio funding is the latest in a flurry of gene therapy investments that have swe...
Tags: Deals, Drugs, Trends, Investing, Venture Capital, Fda, Pfizer, Parkinson's Disease, Biotech, Tpg Capital, Life Sciences, Clinical Trials, Roche, Thermo Fisher Scientific, Biogen, University of North Carolina at Chapel Hill


VC Trends in 2019: More Money, Fewer Deals But Women Still Get Less

If you’ve been following venture capital trends, what you expected to happen in the first quarter of 2019 did: More money is being invested in fewer deals, and women founders still are getting less of it than men.Venture firms sent $32.6 billion into startups nationally during the first three months of 2019, the second largest amount for any quarter since at least 2006, according to data released overnight by PitchBook and the National Venture Capital Association. But that large sum came from o...
Tags: Deals, Startups, Lyft, Uber, Hardware, Entrepreneurship, Softbank, Funding, Women, Trends, Tech, Vc, Software, Physics, Pwc, Venture Capital


Bio Roundup: Gottlieb’s Goodbye, AACR Recap, Migraine Drug Fight & More

Scott Gottlieb’s last day as FDA commissioner is today. His resignation announcement last month surprised some, given the earlier denials about leaving. But after two years of commuting between Connecticut, where his family remained, and the FDA’s Maryland headquarters, he decided to step down from the agency.What will Gottlieb’s legacy be? His efforts to curb teen vaping comes to mind. Or maybe it’s regulation. While Gottlieb remained mindful of the FDA’s oversight role, he also tried to strea...
Tags: Deals, Startups, Maryland, Breast Cancer, Trends, Investing, Lung Cancer, Connecticut, Cigna, Venture Capital, Fda, National, Novartis, Pfizer, Biotech, Insulin


Reveal Biosciences Gets Intel’s Backing on “AI-Powered” Pathology

A 25-person startup developing advanced computing tools to speed up pathology work has raised its first institutional financing from a group of investors led by Intel Capital, the corporate investment arm of the chipmaker.The San Diego-based company, Reveal Biosciences, is among 14 early-stage companies with business plans that include artificial intelligence, a catchall term for a wide range of “intelligent” computer programs, that the tech giant recently selected to back.Intel (NASDAQ: INTC) ...
Tags: Startups, Trends, Tech, Intel, San Diego, INTC, Biotech, CVC, Broadcom, Vmware, Intel Capital, Red Hat, Life Sciences, Diagnostics, Intel NASDAQ, National blog main


NGM Bio’s IPO Raises $107M as NASH Drug Continues Clinical Testing

So far this year, NGM Biopharmaceuticals has licensed a drug to Merck, extended a research agreement with that partner, and laid the groundwork to continue mid-stage testing of its wholly-owned lead compound. Now it can add a $107 million IPO to the list.Late Wednesday, NGM sold appoximately 6.7 million shares for $16 apiece, the high end of the price range the South San Francisco company had planned. Those shares are expected to begin trading on the Nasdaq exchange Thursday under the stock sym...
Tags: Deals, Drugs, Ipo, Cancer, San Francisco, Trends, Investing, Merck, Diabetes, Venture Capital, Fda, Type 2 Diabetes, Biotech, Nasdaq, Life Sciences, Clinical Trials


Why a lab-grown BK Whopper is cause for excitement

Cellular agriculture, or cell-ag, is a new form of lab-grown agricultural products. Burger King is testing its first major foray into the field. A new report lists 90 reasons that cell-ag holds a lot of promise. None Burger King has just announced they're testing a new version of their Whopper that's completely free of actual beef, in 59 locations around St. Louis. Not that even Whopper devotees can tell the difference, according to reports. It's called the "Impossible Whopper." (Impossible ...
Tags: Meat, Environment, Future, Public Health, Harvard, Farming, Innovation, Agriculture, Biotech, St Louis, Burger King, Coli, Whopper, Disaster Relief, Lab-grown, Cell-ag


Why a lab-grown Burger King Whopper is cause for excitement

Burger King is testing its first major foray into the field of beefless patties.On top of plant-based meats, cellular agriculture — or "cell-ag" — can also yield animal-free patties. A new report lists 90 reasons that cell-ag holds a lot of promise. None Burger King has just announced they're testing a new version of their Whopper that's completely free of actual beef, in 59 locations around St. Louis. Not that even Whopper devotees can tell the difference, according to reports. It's called ...
Tags: Meat, Environment, Future, Public Health, Farming, Innovation, Agriculture, Biotech, Whopper, Disaster Relief, Lab-grown, Cell-ag


Why a lab-grown BK Whopper™ is cause for excitement

Cellular agriculture, or cell-ag, is a new form of lab-grown agricultural products. Burger King is testing its first major foray into the field. A new report lists 90 reasons that cell-ag holds a lot of promise. None Burger King has just announced they're testing a new version of their Whopper that's completely free of actual beef, in 59 locations around St. Louis. Not that even Whopper devotees can tell the difference, according to reports. It's called the "Impossible Whopper." (Impossible ...
Tags: Meat, Environment, Future, Public Health, Harvard, Farming, Innovation, Agriculture, Biotech, St Louis, Burger King, Coli, Whopper, Disaster Relief, Lab-grown, Cell-ag


Dyne Therapeutics Emerges With $50M to Take On Rare Muscle Disease

One problem with drugs for muscular disorders is that not enough medicine reaches the muscle, says Romesh Subramanian, CEO of Dyne Therapeutics. Subramanian’s startup has developed a way to deliver drugs to all muscle types, and it is emerging from stealth with $50 million in funding to advance its compounds toward human testing.Dyne was founded last year by Atlas Venture, which seeded and incubated the Cambridge, MA-based biotech. Atlas also invested in Dyne’s Series A funding announced Wednes...
Tags: Deals, Startups, Drugs, Boston, Trends, Investing, Atlas, Netherlands, Venture Capital, Cambridge, Fda, Biotech, Life Sciences, Clinical Trials, Biogen, Alexion Pharmaceuticals


Novartis Adds Inflammation Drugs to Pipeline with Deal for IFM Tre

Less than a year after launching and only days after advancing its lead program into clinical trials, drug developer IFM Tre is in line to be acquired by Novartis.According to an agreement announced Monday, Novartis (NYSE: NVS) will acquire all of the outstanding stock of privately held IFM. The Basel, Switzerland-based pharmaceutical giant will also pay IFM an upfront fee, plus milestone payments pegged to the progress of its experimental drugs. No other financial details of the agreement were...
Tags: Deals, Startups, Boston, Trends, Gout, Novartis, Biotech, Life Sciences, Clinical Trials, Basel Switzerland, Inflammation, National blog main, Boston blog main, Boston top stories, IFM, Novartis NYSE


33 Tech Startups Make San Diego Venture Group “Cool Companies” List

What does it take for a tech startup to be considered “cool?” In the eyes of the San Diego Venture Group, the key element is readiness for venture capital backing.It’s through that lens that the nonprofit organization, whose mission is to connect local startups with venture capitalists who are looking to invest, annually vets tech companies that apply for its “Cool Companies” program. Startups that are accepted are highlighted at SDVG events, including its well-attended annual Venture Summit, a...
Tags: Startups, Trends, Tech, Investing, Venture Capital, San Diego, Angel, Biotech, Fintech, Life Sciences, Gryphon, National blog main, San Diego blog main, San Diego top stories, NeuraLace Medical, Mike Krenn


Biolinq Adds $4.75M to Advance Glucose Monitoring Biosensor Patch

Biosensor startup Biolinq said Thursday it has raised $4.75 million from new investors, including the New York-based Juvenile Diabetes Research Foundation, following the results of a clinical study of its experimental biomarker monitoring device.Founders Jared Tagney and Joshua Windmiller, who met while in grad school at UC San Diego, started the company in 2012 as Electrozyme. The company began focusing on the technology it is currently developing in 2015, Tagney said. It’s seeking to commerci...
Tags: Startups, New York, Trends, Tech, Merck, Diabetes, San Diego, Biotech, Medical Device, Life Sciences, Hikma, JDRF, UC San Diego, UCSD, Juvenile Diabetes Research Foundation, National blog main


Apple Watch ECG capabilities arrive for users across Europe and Hong Kong

Apple’s latest-generation Apple Watch doesn’t just have a curved display and a new industrial design, one of the major features of the Watch when it launched last year were its advanced health-tracking capabilities, particularly in regards to heart health and AFib detection. Those features arrived in the US in December, but users abroad have had to wait. Today, Apple announced that the electro-cardiogram feature and irregular rhythm detection functionality is coming to 19 European countries a...
Tags: Apple, TC, Hong Kong, Europe, US, Tech, Switzerland, Apple Watch, Biotech


Roundup: QL Demo Day, Millendo Therapeutics, Strata Oncology, More

—Millendo Therapeutics, an Ann Arbor-based biopharmaceutical company developing treatments for rare diseases, has initiated a Phase 2b/3 clinical study investigating livoletide (AZP-531) in patients with Prader-Willi syndrome.The study will evaluate the safety and efficacy of the drug on food-related behaviors—primarily hyperphagia, the excessive hunger which is a hallmark of the disease—in Prader-Willi patients. The study, called Zephyr, aims to recruit 150 patients from up to 40 clinical site...
Tags: Startups, Europe, Roundup, Entrepreneurship, Funding, Trends, Tech, Vc, United States, Innovation, Venture Capital, Biotech, Detroit, University Of Michigan, Ann Arbor, National blog main


Thermo Bags Brammer For $1.7B as Gene Therapy Deal Spree Continues

Thermo Fisher Scientific late Sunday evening agreed to buy Brammer Bio for $1.7 billion, yet another bet by a large biopharmaceutical organization on the future of gene therapy.Thermo (NYSE: TMO), a Waltham, MA, developer of lab equipment, made an all-cash offer for Cambridge, MA-based Brammer, a contract manufacturer of gene therapy delivery tools known as viral “vectors.”In a gene therapy procedure, these vectors—engineered viruses—are filled with genetic blueprints and infused into a patient...
Tags: Deals, Boston, Trends, Fda, Pfizer, Biotech, Life Sciences, Clinical Trials, TMO, Roche, Thermo Fisher Scientific, Biogen, Brammer, Cambridge MA, Gene Therapy, National blog main


Corporate biotech venture funding rises again

Joanna Glasner Contributor More posts by this contributor 2019 US VC funds take a more boutique approach VCs aren’t falling in love with dating startups Biotech venture funding has been on a tear for the past couple of years, and corporate investors in the space are doing their part to boost the totals. Here at Crunchbase, we’ve put together an index of the largest pharma and biotech companies active in startup investment, along with their...
Tags: TC, Column, Tech, New Jersey, Venture Capital, GlaxoSmithKline, Novartis, Biotech, 23andMe, Crunchbase, Celgene, Bristol Myers Squibb, Novartis Venture Fund, Joanna Glasner


Our 9 favorite startups from Y Combinator W19 Demo Day 2

Heathcare kiosks, a home-cooked food marketplace, and a way for startups to earn interest on their funding topped our list of high-potential companies from Y Combinator’s Winter 2019 Demo Day 2. 88 startups launched on stage at the lauded accelerator, though some of the best skipped the stage as they’d already raised tons of money. Be sure to check out our write-ups of all 85 startups from day 1 plus our top picks, as well as the full set from day 2. But now, after asking investors and conferrin...
Tags: Apps, Biotech, Food, Funding, GreenTech, Hardware, Health, Logistics, Startups, TC


Pfizer Bolsters Gene Therapy Position with $51M Vivet Deal

Pfizer this morning added to its methodical push into the gene therapy field, paying $51 million for a small stake in Vivet Therapeutics and the option to buy the Parisian biotech in the future.The deal is the latest in a recent string of investments by large biopharma companies in gene therapy, which offers the potential for a long-lasting, if not permanent effect through a one-time treatment. The field has gone through decades of ups and downs, but has now proven that it can develop approved ...
Tags: Deals, New York, Trends, Pfizer, Biotech, Life Sciences, Roche, Biogen, Gene Therapy, National blog main, New York blog main, New York top stories, Boston blog main, Spark Therapeutics, Rare diseases, Duchenne Muscular Dystrophy


JLabs’ Luby Takes the Reins at TMC Innovation Institute in Houston

Houston—Tom Luby, the head of JLabs in Houston, has been named the new director of the Texas Medical Center’s Innovation Institute, the center announced Monday morning.Luby takes over the innovation institute three months after former director Erik Halvorsen left the role.Luby is already a known presence around the TMC innovation building thanks to the two years he has led JLabs @ TMC, the Houston outpost of Johnson & Johnson’s (NYSE: JNJ) network of innovation incubators. The pharmaceutical gi...
Tags: Startups, Texas, Australia, Drugs, Boston, Cancer, Trends, Tech, People, Commercialization, Software, United Kingdom, Healthcare, Innovation, Machine Learning, Houston


Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More

While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb’s proposal to buy Celgene for $74 billion, it wasn’t that long ago that another company’s gaze was fixed on the Summit, NJ, drug maker.In the early 2000s, before the FDA approved Celgene’s flagship multiple myeloma drug lenalidomide (Revlimid), Novartis (NYSE: NVS considered buying the company. It passed, unwilling to risk billions on an unapproved drug. Those details came from biopharma dealmaker George...
Tags: Deals, Startups, China, Ipo, Cancer, Trends, Investing, Merck, Colorectal Cancer, Multiple Sclerosis, Harvard University, Health Insurance, Astrazeneca, Center For Medicare And Medicaid Services, Fda, National


X4 Completes Reverse Merger with Arsanis, Looks Ahead to Phase 3 Test

X4 Pharmaceuticals is the latest biotech to join the public markets, but it didn’t follow the IPO path to get there.Cambridge, MA-based X4 said Wednesday that it completed its “reverse merger” with Arsanis (NASDAQ: ASNS). Such business combinations enable a privately held company to go public by merging with a publicly traded business. Shares of the new X4 are set to begin trading on the Nasdaq exchange Thursday under the stock symbol “XFOR.”X4 is developing drugs that target the CXCR4 pathway,...
Tags: Deals, Drugs, Ipo, Boston, Trends, Cambridge, Biotech, Nasdaq, Life Sciences, Genzyme, National blog main, Boston blog main, Boston top stories, National Organization for Rare Disorders, X4 Pharmaceuticals, X4


Connect, Longtime Local Accelerator, Names Silvia Mah as President

Connect, a 34-year-old nonprofit which runs the well-known Springboard Accelerator Program for startups, announced Monday that it had tapped Silvia Mah, a San Diego investor and entrepreneur, as its new president.She succeeds Greg McKee, who served as president and CEO of the San Diego-based organization for five years before stepping down last month to start a venture capital fund.Mah is executive director of Hera Labs, an accelerator program for women-owned businesses. She’s also a partner in...
Tags: Deals, Trends, Tech, Venture Capital, San Diego, Biotech, Life Sciences, Tim Scott, Mah, National blog main, San Diego blog main, San Diego top stories, Connect, Ad Astra, Greg McKee, Silvia Mah